2021
DOI: 10.1002/ccr3.4830
|View full text |Cite
|
Sign up to set email alerts
|

Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus

Abstract: Colesevelam possesses antidiabetic properties, which could potentiate sulphonylurea or insulin‐induced hypoglycemia; clinically significant hypoglycemia, as a side effect to bile acid sequestrants, may be under‐recognized in clinical practice.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 15 publications
0
2
0
Order By: Relevance
“…The drawbacks of first-generation BASs led to extensive research focused on the design of new more efficient cationic gels. From these gels, only colesevelam hydrochloride and colestilan (or cholestimide) ( Figure 4 ) have been approved for marketing: colesevelam in the US under the trade name WelChol and colestilan in Japan with the trade name Cholebine [ 71 , 72 , 73 , 74 , 75 , 76 ]. These second-generation BASs have an increased affinity to bile salts and fewer adverse effects than first-generation BASs.…”
Section: Lipid-lowering Drugsmentioning
confidence: 99%
“…The drawbacks of first-generation BASs led to extensive research focused on the design of new more efficient cationic gels. From these gels, only colesevelam hydrochloride and colestilan (or cholestimide) ( Figure 4 ) have been approved for marketing: colesevelam in the US under the trade name WelChol and colestilan in Japan with the trade name Cholebine [ 71 , 72 , 73 , 74 , 75 , 76 ]. These second-generation BASs have an increased affinity to bile salts and fewer adverse effects than first-generation BASs.…”
Section: Lipid-lowering Drugsmentioning
confidence: 99%
“…Colesevelam hydrochloride (HCl) is a polyallylamine that has been crosslinked with epichlorohydrin and alkylated with (6-bromohexyl)-trimethylammonium bromide and 1-bromodecane[ 66 ]. In clinical and animal studies on T2DM, obesity, and hyperlipidemia, colesevelam reduced blood glucose[ 67 ], FBG[ 68 ], mediator complex subunit 1, miR-182[ 69 ], HbA1c[ 70 ], hepatic TG, total LDL[ 71 ], very-low-density lipoprotein (VLDL), chylomicron particle[ 72 ], LDL-C[ 73 ], non-HDL-C, ApoB, TGR5/GLP-1-dependent glycogenolysis, FXR-dependent cholesterol, cytochrome P450, Cyp7a1[ 74 ], FGF-19[ 75 ], BA reabsorption[ 76 ], high-sensitivity C-reactive protein[ 77 ], and fructosamine levels[ 78 - 80 ] and increased glycolysis, postmeal glucose tolerance, insulin levels[ 81 ], splanchnic sequestration of meal-derived glucose[ 82 ], GLP-1/GIP levels[ 83 ], total HDL particle levels, miR-96/182/183 expression levels, β-cell function [as revealed by homeostatic model assessment (HOMA)][ 56 ], BA synthesis, ApoA-1 levels[ 54 ], and CCK levels[ 84 ]. As a molecularly engineered, second-generation BA sequestrant, colesevelam has been recommended for reducing LDL-C in patients with primary hypercholesterolemia by inhibiting b-hydroxymethylglutaryl coenzyme A reductase[ 85 ].…”
Section: Bas Metabolites Alleviate Metabolic Diseasesmentioning
confidence: 99%